title: CHEK2 is a multiorgan cancer susceptibility gene.
abstract: A single founder allele of the CHEK2 gene has been associated with predisposition to breast and prostate cancer in North America and Europe. The CHEK2 protein participates in the DNA damage response in many cell types and is therefore a good candidate for a multisite cancer susceptibility gene. Three founder alleles are present in Poland. Two of these result in a truncated CHEK2 protein, and the other is a missense substitution of an isoleucine for a threonine. We ascertained the prevalence of each of these alleles in 4,008 cancer cases and 4,000 controls, all from Poland. The majority of the common cancer sites were represented. Positive associations with protein-truncating alleles were seen for cancers of the thyroid (odds ratio [OR] 4.9; P=.0006), breast (OR 2.2; P=.02), and prostate (OR 2.2; P=.04). The missense variant I157T was associated with an increased risk of breast cancer (OR 1.4; P=.02), colon cancer (OR 2.0; P=.001), kidney cancer (OR 2.1; P=.0006), prostate cancer (OR 1.7; P=.002), and thyroid cancer (OR 1.9; P=.04). The range of cancers associated with mutations of the CHEK2 gene may be much greater than previously thought.
authors.affiliation: International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
authors.forename: C
authors.initials: C
authors.lastname: Cybulski
authors.forename: B
authors.initials: B
authors.lastname: Górski
authors.forename: T
authors.initials: T
authors.lastname: Huzarski
authors.forename: B
authors.initials: B
authors.lastname: Masojć
authors.forename: M
authors.initials: M
authors.lastname: Mierzejewski
authors.forename: T
authors.initials: T
authors.lastname: Debniak
authors.forename: U
authors.initials: U
authors.lastname: Teodorczyk
authors.forename: T
authors.initials: T
authors.lastname: Byrski
authors.forename: J
authors.initials: J
authors.lastname: Gronwald
authors.forename: J
authors.initials: J
authors.lastname: Matyjasik
authors.forename: E
authors.initials: E
authors.lastname: Zlowocka
authors.forename: M
authors.initials: M
authors.lastname: Lenner
authors.forename: E
authors.initials: E
authors.lastname: Grabowska
authors.forename: K
authors.initials: K
authors.lastname: Nej
authors.forename: J
authors.initials: J
authors.lastname: Castaneda
authors.forename: K
authors.initials: K
authors.lastname: Medrek
authors.forename: A
authors.initials: A
authors.lastname: Szymańska
authors.forename: J
authors.initials: J
authors.lastname: Szymańska
authors.forename: G
authors.initials: G
authors.lastname: Kurzawski
authors.forename: J
authors.initials: J
authors.lastname: Suchy
authors.forename: O
authors.initials: O
authors.lastname: Oszurek
authors.forename: A
authors.initials: A
authors.lastname: Witek
authors.forename: S A
authors.initials: SA
authors.lastname: Narod
authors.forename: J
authors.initials: J
authors.lastname: Lubiński
mesh_terms: D016022:Case-Control Studies; D064447:Checkpoint Kinase 2; D017931:DNA Primers; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D016017:Odds Ratio; D011044:Poland; D012150:Polymorphism, Restriction Fragment Length; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*
chemical_list: D017931:DNA Primers; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases